构建专利药价格谈判利益平衡机制的路径选择——基于德国、英国、韩国等典型国家药价谈判机制的启示  

Path Selection of Establishing Interest-balancing Mechanism in Patent Drug Price Negotiation——The Enlightenment of Drug Price Negotiation Management Mechanism Based on Germany, Britain, South Korea and Other Typical Countries

作　　者：伍琳[1] 陈佳妮 雷媛 厉琴慧 陈永法[1] 

机构地区：[1]中国药科大学国际医药商学院

出　　处：《价格理论与实践》2018年第3期83-86,共4页Price:Theory & Practice

基　　金：2015年度国家社会科学基金重大项目(15ZDB167);2015年度国家社会科学基金项目(15BZZ052);2017年度江苏省研究生科研与实践创新计划项目(KYCX17_0736)

摘　　要：本文结合德国、英国、韩国、澳大利亚专利药价格谈判的机制,分析其利益平衡机制建立的关键路径,进而根据我国药价管理改革现状提出针对性的政策建议。研究发现,德英韩澳的专利药价格谈判管理模式虽不尽相同,但为平衡各利益相关方的价值诉求,都引入了权力制衡的管理体系、取向多元的评估模式和公平透明的博弈程序。建议我国在构建法治化的专利药价格谈判体系的基础上,引入定量化的评估工具并加强对于谈判企业的权利救济。Through learning the successful experience of patent drug negotiation management in Australia, South Korea, the United Kingdom and Germany, and analyzing the key elements of the establishment of interest balancing mechanism, this paper puts forward suggestions based on the current situation of drug price reform in China. Despite the different management models, in order to balance the value demands of various stakeholders,check of balance management system, multi-orientation evaluation mode and a fair transparent game procedure have been introduced in Australia, South Korea, UK and Germany. Hence this paper suggests that China should introduce some quantitative assessment tools and strengthen the remedies for negotiating enterprises on the basis of establishing a legalized patent drug price negotiation system.

关 键 词：专利药 价格谈判机制 利益平衡机制 

分 类 号：F416.72[经济管理—产业经济]